Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Safety and Complications of Ocriplasmin

Safety and Complications of Ocriplasmin Opinion EDITORIAL Ocriplasmin, Ocriplasmin; Oh, How Safe Art Thou? Judy E. Kim, MD Our ability to examine the vitreoretinal interface has been However, since the real-world use of the drug began, there greatly improved by the invention of spectral-domain optical have been unfavorable anecdotal reports of visual distur- coherence tomography (OCT). It has allowed earlier and more bances after ocriplasmin injection, including transient but pro- accurate diagnosis of abnormalities of vitreomacular adhe- found visual decline, raising concerns regarding its safety. sion (VMA) that may contribute to vision loss and may ben- While it is not possible to know the frequency of these events efit from intervention. While subtle abnormalities of VMA may in postmarketing surveillance, it is worthwhile to pay atten- be observed, symptomatic VMA or that associated with full- tion to safety-related reports. thickness macular hole (FTMH) requires surgical intervention. In the report of phase 3 trials of ocriplasmin, ocular ad- With improvements in vitreoretinal surgical techniques and verse events such as vitreous floaters, photopsia, conjuncti- better understanding of these conditions, outcomes of surgi- val hemorrhage, blurred vision, and visual impairment were cal management of VMA-related disorders are excellent. How- found to be significantly higher in the treatment http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Safety and Complications of Ocriplasmin

JAMA Ophthalmology , Volume 132 (4) – Apr 1, 2014

Loading next page...
 
/lp/american-medical-association/safety-and-complications-of-ocriplasmin-CLV4EqieSp

References (3)

Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2014.278
pmid
24577332
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Ocriplasmin, Ocriplasmin; Oh, How Safe Art Thou? Judy E. Kim, MD Our ability to examine the vitreoretinal interface has been However, since the real-world use of the drug began, there greatly improved by the invention of spectral-domain optical have been unfavorable anecdotal reports of visual distur- coherence tomography (OCT). It has allowed earlier and more bances after ocriplasmin injection, including transient but pro- accurate diagnosis of abnormalities of vitreomacular adhe- found visual decline, raising concerns regarding its safety. sion (VMA) that may contribute to vision loss and may ben- While it is not possible to know the frequency of these events efit from intervention. While subtle abnormalities of VMA may in postmarketing surveillance, it is worthwhile to pay atten- be observed, symptomatic VMA or that associated with full- tion to safety-related reports. thickness macular hole (FTMH) requires surgical intervention. In the report of phase 3 trials of ocriplasmin, ocular ad- With improvements in vitreoretinal surgical techniques and verse events such as vitreous floaters, photopsia, conjuncti- better understanding of these conditions, outcomes of surgi- val hemorrhage, blurred vision, and visual impairment were cal management of VMA-related disorders are excellent. How- found to be significantly higher in the treatment

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Apr 1, 2014

There are no references for this article.